Revenue climbs at Cryoport (NASDAQ: CYRX) as 2025 results and 2026 outlook set
Rhea-AI Filing Summary
Cryoport, Inc. reported solid growth for 2025 with improving profitability trends. Full-year revenue reached $176.2 million, exceeding the high end of prior guidance and rising 12% year-over-year, while fourth-quarter revenue grew 10% to $45.5 million. Life Sciences Services revenue increased 18% to $96.5 million and Life Sciences Products revenue grew 7% to $79.7 million. Gross margin for 2025 was 47%, supported by cost reduction initiatives and a $12 million year-over-year improvement in adjusted EBITDA from continuing operations to a loss of $5.8 million.
Cryoport’s position in cell and gene therapy strengthened, with revenue from commercial CGT support up 29% to $33.4 million and clinical trial support revenue up 14% to $47.1 million. The company backed 760 global clinical trials at year-end, including 86 in Phase 3, and supported 20 commercial therapies. After the CRYOPDP divestiture and strategic partnership with DHL, cash and cash equivalents rose to $250.5 million and short-term investments to $160.7 million. For 2026, Cryoport issued revenue guidance of $190 million to $194 million.
Positive
- Stronger growth and outlook: 2025 revenue rose 12% to $176.2 million, above the high end of prior guidance, with management guiding 2026 revenue to $190–$194 million, implying continued double-digit expansion if achieved.
- Improving profitability and cash position: Gross margin reached 47% and adjusted EBITDA from continuing operations improved by $12 million to a $5.8 million loss, while net income was $78.3 million and cash plus short-term investments totaled over $411 million at year-end 2025.
Negative
- None.
Insights
Revenue beat guidance, margins improved, and balance sheet is much stronger.
Cryoport delivered 2025 revenue of
Profitability metrics moved in the right direction. Gross margin reached
The balance sheet strengthened notably following the CRYOPDP divestiture and DHL partnership, with cash and cash equivalents at
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
| (Address of principal executive offices, including zip code) | ||||
| Registrant’s telephone number, including area code: ( | ||||
| Not Applicable | ||||
| (Former name or former address, if changed since last report) | ||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On March 3, 2026, Cryoport, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1.
The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
| Item 9.01. | Financial Statements and Exhibits |
| (d) | Exhibits. | The following material is filed as an exhibit to this Current Report on Form 8-K: |
Exhibit
Number
| 99.1 | Press Release dated March 3, 2026 issued by the Company. |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 3, 2026 | Cryoport, Inc. |
| /s/ Robert Stefanovich | |
| Robert Stefanovich | |
| Chief Financial Officer |
Exhibit 99.1
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
| ● | FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance |
| ● | Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue |
| ● | Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 |
| ● | Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 |
| ● | Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) |
NASHVILLE, Tennessee, March 3, 2026, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.
Jerrell Shelton, CEO of Cryoport, commented, “2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2 million, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets. We achieved double-digit revenue growth driven by expanding cell and gene therapy (“CGT”) activity, with revenue from the support of commercial CGTs increasing 29% year-over-year to a record $33.4 million for FY 2025. Revenue from the support of clinical trials also remained solid, growing 14% to $47.1 million for FY 2025. At year-end, we supported a record 760 global clinical trials, representing approximately 70% of CGT trials. We believe our leadership position across both clinical and commercial programs, and the breadth of the development pipeline we support, provide a substantial foundation for sustained long-term growth.
“We continued to execute on our strategy of expanding our revenue streams and capturing more revenue per client as our Life Sciences Services revenue increased 18% year-over-year for FY 2025, including 22% growth in BioStorage/BioServices revenue. This performance reflects the expanding scale of the clinical and commercial programs we support and the increasing value customers place on our differentiated high-end supply chain solutions. While our primary focus remains on accelerating revenue growth and strengthening our market position, we continue to enhance operational discipline across the organization as we advance on our pathway to profitability. In 2025, our cost reduction initiatives contributed to our consolidated gross margin of 47% and a $12 million year-over-year improvement in adjusted EBITDA from continuing operations.
1
“Despite macro challenges, our Life Sciences Products segment grew 7% year-over-year and continues to support our Services businesses. MVE Biological Solutions’ (MVE) focus on innovation and execution continues to further enhance its position as the global leader in the production of high- quality cryogenic systems. Recently MVE introduced integrated Condition Monitoring Solutions for its dry vapor shippers and also launched the Fusion® 800 Series, a revolutionary self-sustaining cryogenic freezer that can fit through a single door, which opens up substantial market opportunities.
“We also increased our investments into Cryoport Systems to support the traction that we are seeing across our broad portfolio of CGT clients. These targeted investments include the launch of our Global Supply Chain Center in Paris, France, the expansion of our Belgian operations to accommodate a key commercial client, and the facility buildout to consolidate three existing facilities in Irvine, California into one expansive Global Supply Chain Center in Santa Ana, California.
“Importantly, in 2025 we formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, providing a substantial capital infusion. Over time, we believe this relationship will enhance our positioning in the EMEA and APAC regions and strengthen our competitive industry profile. As part of our continuing strategic initiative to embed our market-leading solutions into the CGT ecosystem and improve our growth trajectory, we expanded our global partnerships by entering into strategic collaborations with Cardinal Health and Parexel.
“As we enter 2026 and balance the global macro puts and takes, we believe that our full-year revenue guidance of $190 million to $194 million is an appropriate starting point for the year,” concluded Mr. Shelton.
In tabular form, Q4 2025 and FY 2025 revenue compared to Q4 2024 and FY 2024, respectively, were as follows:
Cryoport, Inc. and Subsidiaries
Revenue
| Three Months Ended December 31, (unaudited) | Years Ended December 31, | |||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||||||||
| Life Sciences Services | $ | 25,005 | $ | 21,476 | 16 | % | $ | 96,497 | $ | 82,044 | 18 | % | ||||||||||||
| BioLogistics Solutions | 20,305 | 17,479 | 16 | % | 78,137 | 67,019 | 17 | % | ||||||||||||||||
| BioStorage/BioServices | 4,700 | 3,997 | 18 | % | 18,360 | 15,025 | 22 | % | ||||||||||||||||
| Life Sciences Products | $ | 20,445 | $ | 19,976 | 2 | % | $ | 79,680 | $ | 74,725 | 7 | % | ||||||||||||
| Total Revenue | $ | 45,450 | $ | 41,452 | 10 | % | $ | 176,177 | $ | 156,769 | 12 | % | ||||||||||||
2
BioLogistics Solutions revenue increased 17% year-over-year for FY 2025, supported by increasing customer activity and program advancement within the CGT market. BioStorage/BioServices revenue continued to experience strong year-over-year growth, increasing 22% for FY 2025, reflecting our clients’ interest in our expanded and integrated services offering that provides a seamless and secure handling of temperature-sensitive materials through our global network.
Revenue from the support of commercial CGTs increased 29% year-over-year to $33.4 million and we supported twenty (20) commercial therapies as of December 31, 2025.
As of year-end, Cryoport supported a total of 760 global clinical trials, a net increase of 59 clinical trials over FY 2024, with 86 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:
Cryoport Supported Clinical Trials by Phase
| December 31, | ||||||||||
| Clinical Trials | 2023 | 2024 | 2025 | |||||||
| Phase 1 | 282 | 299 | 313 | |||||||
| Phase 2 | 311 | 321 | 361 | |||||||
| Phase 3 | 82 | 81 | 86 | |||||||
| Total | 675 | 701 | 760 | |||||||
Cryoport Supported Clinical Trials by Region
| December 31, | ||||||||||
| Clinical Trials | 2023 | 2024 | 2025 | |||||||
| Americas | 519 | 537 | 571 | |||||||
| EMEA | 112 | 116 | 138 | |||||||
| APAC | 44 | 48 | 51 | |||||||
| Total | 675 | 701 | 760 | |||||||
In Q4 2025, five Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. Post quarter-end, two additional BLA filings have occurred. During the fourth quarter, Cryoport's customer, Fondazione Telethon received FDA approval for their gene therapy Waskyra for the treatment of Wiskott-Aldrich Syndrome (WAS). During the fourth quarter, Bristol Myers Squibb received supplemental approval from the European Commission (EC) to expand the label of Breyanzi® as a third line treatment for relapsed or refractory follicular lymphoma. Lastly, in late December, Cryoport’s customer Inovio Pharmaceuticals’ BLA filing for INO-3107 was accepted by the FDA as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). For 2026, we anticipate 13 BLA/MAA application filings (including the two already filed), nine new therapy approvals and an additional two approvals for label/geographic expansions. In the near term, Cryoport has three clients that are anticipating new therapy approval decisions in March and April 2026.
3
Operational milestones
Life Sciences Services
| ● | Launched state-of-the-art Global Supply Chain Center at the Charles de Gaulle airport in Paris, France, with our fourth Global Supply Chain Center in Santa Ana, California targeted for opening in late 2026. |
| ● | IntegriCell®, with cryopreservation service centers located near Liège, Belgium and in Houston, Texas, onboarded its first clients from whom we will have revenues throughout 2026. |
| ● | Launched cGMP sterile fulfillment/kitting services out of our Liège, Belgium facility supporting manufacturing needs for a key commercial client and the broader market. |
| ● | Cryoport Systems successfully achieved certification under ISO 21973:2020, the international standard for transportation of cells for therapeutic use published by the International Organization for Standardization (ISO), underscoring its commitment to safety and traceability within supply chain management of the rapidly expanding CGT industry. |
Life Sciences Products
| ● | MVE Biological Solutions (MVE) introduced its integrated Condition Monitoring Solutions for its SC 4/2V and 4/3V dry vapor shippers, combining MVE's trusted cryogenic systems with advanced, real-time condition monitoring technology supplied by Tec4med, a Cryoport company. |
| ● | MVE launched its new Fusion® 800 Series, the next evolution of MVE’s patented, award-winning Fusion technology, a self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments. |
4
Financial Highlights
On June 11, 2025, the Company completed its previously announced divestiture of its specialty courier CRYOPDP business to DHL Supply Chain International Holding B.V. (“DHL”) as a part of a strategic partnership with DHL. The divestiture and strategic partnership are expected to enhance the Company’s ability to develop its business, particularly in the EMEA and APAC regions, and to provide differentiated and high-value services aligned with Cryoport’s long-term growth strategy. The results of CRYOPDP, a former business within Cryoport’s Life Sciences Services segment, are presented as discontinued operations for all periods presented within the Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets included in this press release and are also not included in the non-GAAP financial measures presented herein.
Revenue
| ● | Total revenue for Q4 2025 was $45.5 million, compared to $41.5 million for Q4 2024, a year-over-year increase of 10%, or $4.0 million. |
| o | Life Sciences Services revenue for Q4 2025 (representing 55% of our total revenue) was $25.0 million, compared to $21.5 million for Q4 2024, up 16% year-over-year, including BioStorage/BioServices revenue of $4.7 million, up 18% year-over-year. |
| o | Life Sciences Products revenue for Q4 2025 (representing 45% of our total revenue) was $20.4 million, compared to $20.0 million for Q4 2024, up 2% year-over-year. |
| ● | Total revenue for FY 2025 was $176.2 million, compared to $156.8 million for FY 2024, a year-over-year increase of 12%, or $19.4 million. |
| o | Life Sciences Services revenue for FY 2025 was $96.5 million, compared to $82.0 million for FY 2024, up 18% year-over-year, including BioStorage/BioServices revenue of $18.4 million for FY 2025, compared to $15.0 million for FY 2024, up 22% year-over-year. |
| o | Life Sciences Products revenue for FY 2025 was $79.7 million, compared to $74.7 million for FY 2024, up 7% year-over-year. |
Gross Margin
| ● | Total gross margin was 47.8% for Q4 2025, compared to 47.0% for Q4 2024. |
| o | Gross margin for Life Sciences Services was 48.6% for Q4 2025, compared to 48.8% for Q4 2024. |
| o | Gross margin for Life Sciences Products was 46.8% for Q4 2025, compared to 45.1% for Q4 2024. |
| ● | Total gross margin was 47.1% for FY 2025 compared to 44.4% for FY 2024. |
| o | Gross margin for Life Sciences Services was 48.8% for FY 2025, compared to 46.9% for FY 2024. |
| o | Gross margin for Life Sciences Products was 45.2% for FY 2025, compared to 41.7% for FY 2024. |
5
Operating Costs and Expenses
| ● | Operating costs and expenses were $31.7 million for Q4 2025, compared to $32.2 million for Q4 2024. Operating costs and expenses for FY 2025 decreased to $119.9 million, compared to $191.3 million for FY 2024. The decrease for FY 2025 reflects an impairment charge of $63.8 million in Q2 2024, which was primarily related to the write off of remaining goodwill for MVE. Excluding the impairment charge, non-GAAP adjusted operating costs and expenses for FY 2025 were $119.9 million, compared to $127.5 million for FY 2024. |
Loss from Continuing Operations
| ● | Loss from continuing operations was $8.5 million for Q4 2025, compared to a loss of $17.2 million for Q4 2024. Loss from continuing operations for FY 2025 was $34.0 million compared to a loss of $104.7 million for FY 2024. |
Net Income (Loss) – including Discontinued Operations
| ● | Net loss for Q4 2025 was $11.6 million and net income for FY 2025 was $78.3 million, compared to net losses of $18.7 million and $114.8 million for the same periods in 2024, respectively. Net income for FY 2025 was primarily driven by the divestiture of our CRYOPDP specialty courier business during Q2 2025, which contributed $112.3 million, net of taxes, to income from discontinued operations. |
| ● | Net loss attributable to common stockholders for Q4 2025 was $13.6 million, or $0.27 per share. Net income attributable to common stockholders for FY 2025 was $70.3 million, or $1.40 per share. This compares to net losses attributable to common stockholders of $20.7 million, or $0.42 per share, and $122.8 million, or $2.49 per share, for Q4 2024 and FY 2024, respectively. |
| ● | Non-GAAP adjusted net loss was $34.0 million for FY 2025, compared to $69.5 million for FY 2024. |
Adjusted EBITDA from Continuing Operations
| ● | Adjusted EBITDA from continuing operations was a negative $1.4 million for Q4 2025, compared to a negative $2.9 million for Q4 2024. Adjusted EBITDA from continuing operations for FY 2025 was a negative $5.8 million, compared to a negative $17.8 million for FY 2024. |
Cash, Cash equivalents, and Short-Term Investments
| ● | Cryoport held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025. |
Share Repurchase Programs
| ● | During 2025, the Company purchased 1,340,608 shares of its common stock under its repurchase programs, at an average price of $7.45 per share, for an aggregate amount of $10.0 million. These shares were returned to the status of authorized but unissued shares of common stock. Following these repurchases, the Company had approximately $63.9 million in total repurchase authorization available under its remaining repurchase program. |
6
Guidance for Full-Year Fiscal 2026
| ● | The Company provides full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. |
Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.
Additional Information
Further information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which is expected to be filed with the SEC on March 6, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.
Earnings Conference Call Information
IMPORTANT INFORMATION: In addition to the earnings release, a document titled “Cryoport Fourth Quarter and Full Year 2025 in Review”, providing a review of Cryoport’s business update, will be issued at 4:05 p.m. ET on Tuesday, March 3, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call at 5:00 p.m. ET on March 3, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.
7
Conference Call Information
| Date: | Tuesday, March 3, 2026 |
| Time: | 5:00 p.m. ET |
| Dial-in numbers: | 1-800-717-1738 (U.S.), 1-646-307-1865 (International) |
| Confirmation code: | Request the “Cryoport Call” or Conference ID: 1189463 |
| Live webcast: | ‘Investor Relations’ section at www.cryoportinc.com or click here.
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software. |
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until March 10, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1189463#.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX is a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.
8
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company’s expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the “DHL Transaction”), the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company’s expectation of revenue contribution from IntegriCell’s cryopreservation service centers throughout 2026. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any U.S federal government shutdown, variations in the Company's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties relating to the DHL Transaction include, but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business relationships, including with employees and suppliers. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.
Cryoport Investor Contacts:
Todd Fromer / Scott Eckstein
KCSA Strategic Communications
cryoport@kcsa.com
9
Cryoport, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
| Three Months Ended December 31, (unaudited) | Years Ended December 31, | |||||||||||||||
| (in thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | ||||||||||||||||
| Life Sciences Services revenue | $ | 25,005 | $ | 21,476 | $ | 96,497 | $ | 82,044 | ||||||||
| Life Sciences Products revenue | 20,445 | 19,976 | 79,680 | 74,725 | ||||||||||||
| Total revenue | 45,450 | 41,452 | 176,177 | 156,769 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Cost of services revenue | 12,859 | 10,987 | 49,429 | 43,564 | ||||||||||||
| Cost of products revenue | 10,880 | 10,972 | 43,694 | 43,548 | ||||||||||||
| Total cost of revenue | 23,739 | 21,959 | 93,123 | 87,112 | ||||||||||||
| Gross margin | 21,711 | 19,493 | 83,054 | 69,657 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Selling, general and administrative | 27,276 | 28,091 | 102,819 | 109,809 | ||||||||||||
| Engineering and development | 4,466 | 4,155 | 17,041 | 17,710 | ||||||||||||
| Impairment loss | - | - | - | 63,809 | ||||||||||||
| Total operating costs and expenses: | 31,742 | 32,246 | 119,860 | 191,328 | ||||||||||||
| Loss from operations | (10,031 | ) | (12,753 | ) | (36,806 | ) | (121,671 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Investment income | 3,357 | 1,427 | 9,798 | 9,895 | ||||||||||||
| Interest expense | (634 | ) | (578 | ) | (2,361 | ) | (3,977 | ) | ||||||||
| Gain on extinguishment of debt, net | - | - | - | 18,505 | ||||||||||||
| Other income (expense), net | (87 | ) | (5,402 | ) | (2,801 | ) | (7,101 | ) | ||||||||
| Income (loss) before provision for income taxes | (7,395 | ) | (17,306 | ) | (32,170 | ) | (104,349 | ) | ||||||||
| Provision for income taxes | (1,126 | ) | 134 | (1,799 | ) | (359 | ) | |||||||||
| Income (loss) from continuing operations | $ | (8,521 | ) | $ | (17,172 | ) | $ | (33,969 | ) | $ | (104,708 | ) | ||||
| Income (loss) from discontinued operations, net | (3,123 | ) | (1,497 | ) | 112,270 | (10,048 | ) | |||||||||
| Net income (loss) | $ | (11,644 | ) | $ | (18,669 | ) | $ | 78,301 | $ | (114,756 | ) | |||||
| Paid-in-kind dividend on Series C convertible preferred stock | (2,000 | ) | (2,000 | ) | (8,000 | ) | (8,000 | ) | ||||||||
| Net income (loss) attributable to common stockholders | $ | (13,644 | ) | $ | (20,669 | ) | $ | 70,301 | $ | (122,756 | ) | |||||
| Net income (loss) per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | (0.27 | ) | $ | (0.42 | ) | $ | 1.40 | $ | (2.49 | ) | |||||
| Weighted average common shares issued and outstanding: | ||||||||||||||||
| Basic | 49,759,264 | 49,616,806 | 50,071,665 | 49,349,624 | ||||||||||||
10
Cryoport, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
| December 31, | ||||||||
| (in thousands) | 2025 | 2024 | ||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 250,494 | $ | 34,137 | ||||
| Short-term investments | 160,714 | 216,460 | ||||||
| Accounts receivable, net | 33,359 | 25,304 | ||||||
| Inventories | 23,188 | 21,476 | ||||||
| Prepaid expenses and other current assets | 8,419 | 7,943 | ||||||
| Current assets held for sale | - | 36,251 | ||||||
| Total current assets | 476,174 | 341,571 | ||||||
| Property and equipment, net | 85,448 | 80,013 | ||||||
| Operating lease right-of-use assets | 39,720 | 39,920 | ||||||
| Intangible assets, net | 138,082 | 147,927 | ||||||
| Goodwill | 22,400 | 20,569 | ||||||
| Deposits | 2,092 | 1,951 | ||||||
| Deferred tax assets | 1,073 | 842 | ||||||
| Long-term assets held for sale | - | 70,699 | ||||||
| Total assets | $ | 764,989 | $ | 703,492 | ||||
| Current liabilities | ||||||||
| Accounts payable and other accrued expenses | $ | 15,283 | $ | 15,895 | ||||
| Accrued compensation and related expenses | 12,980 | 11,209 | ||||||
| Deferred revenue | 943 | 1,061 | ||||||
| Current portion of operating lease liabilities | 4,133 | 3,399 | ||||||
| Current portion of finance lease liabilities | 422 | 315 | ||||||
| Current portion of convertible senior notes, net | 185,094 | 14,298 | ||||||
| Current portion of notes payable | 163 | 143 | ||||||
| Current portion of contingent consideration | - | 2,808 | ||||||
| Current liabilities held for sale | - | 15,435 | ||||||
| Total current liabilities | 219,018 | 64,563 | ||||||
| Convertible senior notes, net | - | 183,919 | ||||||
| Notes payable, net | 1,087 | 1,114 | ||||||
| Operating lease liabilities, net | 39,078 | 38,551 | ||||||
| Finance lease liabilities, net | 741 | 800 | ||||||
| Deferred tax liabilities | 1,354 | 804 | ||||||
| Other long-term liabilities | 444 | 295 | ||||||
| Contingent consideration, net | 629 | 3,751 | ||||||
| Long-term liabilities held for sale | - | 7,797 | ||||||
| Total liabilities | 262,351 | 301,594 | ||||||
| Total stockholders' equity | 502,638 | 401,898 | ||||||
| Total liabilities and stockholders' equity | $ | 764,989 | $ | 703,492 | ||||
11
Note Regarding Use of Non-GAAP Financial Measures
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 are included in this release: adjusted operating costs and expenses, adjusted net loss, and adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted operating costs and expenses, adjusted net loss, and adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
Adjusted operating costs and expenses is defined as operating costs and expenses, excluding impairment losses, if any. Adjusted net loss is defined as net income (loss), excluding impairment losses, net gain on extinguishment of debt, and income (loss) from discontinued operations, including gain on sale, if any. Management believes these measures, when read in conjunction with, and as supplemental to, the corresponding GAAP financial measures, provide useful measures to investors of Cryoport's expenses and operating results, meaningful comparisons with historical results, and insight into Cryoport's operating performance.
Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized loss on investments, foreign currency loss, net gain on extinguishment of debt, impairment loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.
Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company’s board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.
12
Cryoport, Inc. and Subsidiaries
Reconciliation of GAAP operating cost and expenses to Non-GAAP adjusted operating cost and expenses
| Three Months Ended December 31, (unaudited) | Years Ended December 31, | |||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| GAAP operating costs and expenses | $ | 31,742 | $ | 32,246 | $ | 119,860 | $ | 191,328 | ||||||||
| Non-GAAP adjustments to operating costs and expenses | ||||||||||||||||
| Impairment loss | — | — | — | (63,809 | ) | |||||||||||
| Non-GAAP adjusted operating costs and expenses | $ | 31,742 | $ | 32,246 | $ | 119,860 | $ | 127,519 | ||||||||
Cryoport, Inc. and Subsidiaries
Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)
| Three Months Ended December 31, (unaudited) | Years Ended December 31, | |||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| GAAP net income (loss) | $ | (11,644 | ) | $ | (18,670 | ) | $ | 78,301 | $ | (114,756 | ) | |||||
| Non-GAAP adjustments to net income (loss) | ||||||||||||||||
| Income (loss) from discontinued operations, including gain on sale | (3,123 | ) | — | 112,270 | — | |||||||||||
| Gain on extinguishment of debt, net | — | — | — | 18,505 | ||||||||||||
| Impairment loss | — | — | — | (63,809 | ) | |||||||||||
| Non-GAAP adjusted net loss | $ | (8,521 | ) | $ | (18,670 | ) | $ | (33,969 | ) | $ | (69,452 | ) | ||||
13
Cryoport, Inc. and Subsidiaries
Reconciliation of GAAP loss from continuing operations to adjusted EBITDA
(unaudited)
| Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| GAAP loss from continuing operations | $ | (8,521 | ) | $ | (17,172 | ) | $ | (33,969 | ) | $ | (104,708 | ) | ||||
| Non-GAAP adjustments to loss: | ||||||||||||||||
| Depreciation and amortization expense | 6,355 | 5,992 | 25,153 | 23,565 | ||||||||||||
| Acquisition and integration costs | 6 | 3 | 75 | 655 | ||||||||||||
| Cost reduction initiatives | — | 310 | 642 | 842 | ||||||||||||
| Investment income | (3,357 | ) | (1,427 | ) | (9,798 | ) | (9,895 | ) | ||||||||
| Unrealized loss on investments | 82 | 2,445 | 702 | 5,038 | ||||||||||||
| Foreign currency loss | 248 | 3,130 | 2,769 | 2,352 | ||||||||||||
| Interest expense, net | 634 | 579 | 2,361 | 3,977 | ||||||||||||
| Stock-based compensation expense | 2,431 | 3,644 | 10,066 | 16,567 | ||||||||||||
| Gain on extinguishment of debt, net | — | — | — | (18,505 | ) | |||||||||||
| Impairment loss | — | — | — | 63,809 | ||||||||||||
| Change in fair value of contingent consideration | — | (225 | ) | (5,178 | ) | (1,827 | ) | |||||||||
| Income taxes | 1,126 | (134 | ) | 1,799 | 359 | |||||||||||
| Other adjustments | (401 | ) | — | (401 | ) | — | ||||||||||
| Adjusted EBITDA from continuing operations | $ | (1,397 | ) | $ | (2,855 | ) | $ | (5,779 | ) | $ | (17,771 | ) | ||||
14
FAQ
How did Cryoport (CYRX) perform financially in full-year 2025?
What were Cryoport’s key revenue drivers in 2025?
What guidance did Cryoport provide for its 2026 revenue?
How strong is Cryoport’s balance sheet after the CRYOPDP divestiture?
What is Cryoport’s role in cell and gene therapy clinical trials?
Did Cryoport achieve profitability in 2025?
Filing Exhibits & Attachments
4 documents